Dy G.W. Gore J.L. Forouzanfar M.H. et al.

Global burden of urologic cancers, 1990–2013.

Eur Urol. 71: 437-446Savir-Baruch B. Werner R.A. Rowe S.P. et al.

PET imaging for prostate cancer.

Radiologic Clin. 59: 801-811Sharma S. Zapatero-Rodriguez J. O'Kennedy R.

Prostate cancer diagnostics: Clinical challenges and the ongoing need for disruptive and effective diagnostic tools.

Biotechnol Adv. 35: 135-149Picchio M. Mapelli P. Panebianco V. et al.

Imaging biomarkers in prostate cancer: role of PET/CT and MRI.

Eur J Nucl Med Mol Imaging. 42: 644-655Wibmer A.G. Burger I.A. Sala E. et al.

Molecular imaging of prostate cancer.

Radiographics. 36: 142Mhawech-Fauceglia P. Zhang S. Terracciano L. et al.

Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using multiple tumour tissue microarray technique.

Histopathology. 50: 472-483Ferreira G. Iravani A. Hofman M.S. et al.

Intra-individual comparison of 68 Ga-PSMA-11 and 18 F-DCFPyL normal-organ biodistribution.

Cancer Imaging. 19: 1-10von Eyben F.E. Picchio M. von Eyben R. et al.

68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta-analysis.

Eur Urol focus. 4: 686-693Uprimny C. Kroiss A.S. Decristoforo C. et al.

68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.

Eur J Nucl Med Mol Imaging. 44: 941-949Peng L. Li J. Meng C. et al.

Can 68Ga-prostate specific membrane antigen positron emission tomography/computerized tomography provide an accurate lymph node staging for patients with medium/high risk prostate cancer? A diagnostic meta-analysis.

Radiat Oncol. 15: 1-10Zhao R. Li Y. Nie L. et al.

The meta-analysis of the effect of 68Ga-PSMA-PET/CT diagnosis of prostatic cancer compared with bone scan.

Medicine. 100Manafi-Farid R. Ranjbar S. Jamshidi Araghi Z. et al.

Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends.

Cancers. 13: 5360Morris M.J. Rowe S.P. Gorin M.A. et al.

Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: Results from the CONDOR phase III, multicenter study.

Clin Cancer Res. 27: 3674-3682Pienta K.J. Gorin M.A. Rowe S.P. et al.

A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with 18F-DCFPyL in prostate cancer patients (OSPREY).

J Urol. 206: 52-61Sun J. Lin Y. Wei X. et al.

Performance of 18F-DCFPyL PET/CT Imaging in Early Detection of Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-Analysis.

Front Oncol. 11: 649171Awenat S. Piccardo A. Carvoeiras P. et al.

Diagnostic role of 18F-PSMA-1007 PET/CT in prostate cancer staging: a systematic review.

Diagnostics. 11: 552Giesel F.L. Hadaschik B. Cardinale J. et al.

F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.

Eur J Nucl Med Mol Imaging. 44: 678-688Manyak M.J. Hinkle G.H. Olsen J.O. et al.

Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer.

Urology. 54: 1058-1063Morris M.J. Pandit-Taskar N. Carrasquillo J.A. et al.

Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology. 31: 31Bratanovic I.J. Zhang C. Zhang Z. et al.

A Radiotracer for Molecular Imaging and Therapy of Gastrin-Releasing Peptide Receptor–Positive Prostate Cancer.

J Nucl Med. 63: 424-430Kähkönen E. Jambor I. Kemppainen J. et al.

In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548.

Clin Cancer Res. 19: 5434-5443Touijer K.A. Michaud L. Alvarez H.A.V. et al.

Prospective study of the radiolabeled GRPR antagonist BAY86-7548 for positron emission tomography/computed tomography imaging of newly diagnosed prostate cancer.

Eur Urol Oncol. 2: 166-173Stephens A. Loidl W.C. Beheshti M. et al.

Detection of prostate cancer with the [68Ga]-labeled bombesin antagonist RM2 in patients undergoing radical prostatectomy.

Journal of Clinical Oncology. 34: 80Baratto L. Song H. Duan H. et al.

A prospective study of 68Ga-RM2 PET/MRI in patients with biochemically recurrent prostate cancer and negative conventional imaging.

Journal of Clinical Oncology. 38: e17536Parihar A.S. Schmidt L.R. Dehdashti F. et al.

Detection of additional primary neoplasms on 18F-Fluciclovine PET/CT in patients with primary prostate cancer.

J Nucl Med. 63: 713-719Laudicella R. Albano D. Alongi P. et al.

18F-Facbc in prostate cancer: a systematic review and meta-analysis.

Cancers. 11: 1348Gusman M. Aminsharifi J.A. Peacock J.G. et al.

Review of 18F-fluciclovine PET for detection of recurrent prostate cancer.

Radiographics. 39: 822-841Calais J. Ceci F. Eiber M. et al.

18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.

Lancet Oncol. 20: 1286-1294Wallitt K.L. Khan S.R. Dubash S. et al.

Clinical PET imaging in prostate cancer.

Radiographics. 37: 1512-1536

Is There Use for FDG-PET in Prostate Cancer?.

Semin Nucl Med. 46: 502-506Bertagna F. Sadeghi R. Giovanella L. et al.

Incidental uptake of 18F-fluorodeoxyglucose in the prostate gland.

Nuklearmedizin-NuclearMedicine. 53: 249-258Shen K. Liu B. Zhou X. et al.

The evolving role of 18F-FDG PET/CT in diagnosis and prognosis prediction in progressive prostate cancer.

Front Oncol. 11: 683793

The use of hyperpolarised 13C-MRI in clinical body imaging to probe cancer metabolism.

Br J Cancer. 124: 1187-1198Sushentsev N. McLean M.A. Warren A.Y. et al.

Hyperpolarised 13C-MRI identifies the emergence of a glycolytic cell population within intermediate-risk human prostate cancer.

Nat Commun. 13: 1-12Chen H.-Y. Aggarwal R. Bok R.A. et al.

Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study.

Prostate Cancer prostatic Dis. 23: 269-276

Prostate cancer: PET with 18F-FDG, 18F-or 11C-acetate, and 18F-or 11C-choline.

J Nucl Med. 52: 81-89Evangelista L. Cervino A.R. Burei M. et al.

Comparative studies of radiolabeled choline positron emission tomography, histology of primary tumor and other imaging modalities in prostate cancer: a systematic review and meta-analysis.

Clin Translational Imaging. 1: 99-109Kato T. Tsukamoto E. Kuge Y. et al.

Accumulation of [11C] acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer.

Eur J Nucl Med Mol Imaging. 29: 1492-1495Mohsen B. Giorgio T. Rasoul Z.S. et al.

Application of C-11-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature.

BJU Int. 112: 1062-1072Haseebuddin M. Dehdashti F. Siegel B.A. et al.

11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction.

J Nucl Med. 54: 699-706Strandberg S. Karlsson C.T. Ogren M. et al.

11C-acetate-PET/CT compared to 99mTc-HDP bone Scintigraphy in primary staging of high-risk prostate cancer.

Anticancer Res. 36: 6475-6479Beheshti M. Rezaee A. Geinitz H. et al.

Evaluation of prostate cancer bone metastases with 18F-NaF and 18F-fluorocholine PET/CT.

J Nucl Med. 57: 55S-60SSheikhbahaei S. Jones K.M. Werner R.A. et al.

18F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies.

Ann Nucl Med. 33: 351-361Gauthé M. Sargos P. Barret E. et al.

Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review.

J Clin Med. 10: 4909Vargas H.A. Wassberg C. Fox J.J. et al.

Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival.

Radiology. 271: 220-229Larson S.M. Morris M. Gunther I. et al.

Tumor localization of 16β-18F-fluoro-5α-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer.

J Nucl Med. 45: 366-373Dehdashti F. Picus J. Michalski J.M. et al.

Positron tomographic assessment of androgen receptors in prostatic carcinoma.

Eur J Nucl Med Mol Imaging. 32: 344-350Persson M. Skovgaard D. Brandt-Larsen M. et al.

First-in-human uPAR PET: imaging of cancer aggressiveness.

Theranostics. 5: 1303Fosbøl M.Ø. Kurbegovic S. Johannesen H.H. et al.

Urokinase-type plasminogen activator receptor (uPAR) PET/MRI of prostate cancer for noninvasive evaluation of aggressiveness: comparison with Gleason score in a prospective phase 2 clinical trial.

J Nucl Med. 62: 354-359Zheng D.-Q. Woodard A.S. Fornaro M. et al.

Prostatic carcinoma cell migration via αvβ3integrin is modulated by a focal adhesion kinase pathway.

Cancer Res. 59: 1655-1664Beer A.J. Schwarzenböck S.M. Zantl N. et al.

Non-invasive assessment of inter-and intrapatient variability of integrin expression in metastasized prostate cancer by PET.

Oncotarget. 7: 28151Klinkhammer B.M. Lammers T. Mottaghy F.M. et al.

Non-invasive molecular imaging of kidney diseases.

Nat Rev Nephrol. 17: 688-703Stillebroer A.B. Mulders P.F. Boerman O.C. et al.

Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.

Eur Urol. 58: 75-83van Oostenbrugge T. Mulders P.

Targeted PET/CT imaging for clear cell renal cell carcinoma with radiolabeled antibodies: recent developments using girentuximab.

Curr Opin Urol. 31: 249-254Divgi C.R. Pandit-Taskar N. Jungbluth A.A. et al.

Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial.

Lancet Oncol. 8: 304-310van Oostenbrugge T.J. Langenhuijsen J.F. Oosterwijk E. et al.

Follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with 111In-girentuximab.

Eur J Nucl Med Mol Imaging. 47: 1864-1870Hekman M.C. Rijpkema M. Aarntzen E.H. et al.

Positron emission tomography/computed tomography with 89Zr-girentuximab can aid in diagnostic dilemmas of clear cell renal cell carcinoma suspicion.

Eur Urol. 74: 257-260Turkbey B. Lindenberg M.L. Adler S. et al.

PET/CT imaging of renal cell carcinoma with 18F-VM4-037: a phase II pilot study.

Abdom Radiol. 41: 109-118Tabei T. Nakaigawa N. Kaneta T. et al.

Early assessment with 18 F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab.

BMC cancer. 19: 1-9Wang H.-Y. Ding H.-J. Chen J.-H. et al.

Meta-analysis of the diagnostic performance of [18F] FDG-PET and PET/CT in renal cell carcinoma.

Cancer Imaging. 12: 464Hwang S.H. Cho A. Yun M. et al.

Prognostic value of pretreatment metabolic tumor volume and total lesion glycolysis using 18F-FDG PET/CT in patients with metastatic renal cell carcinoma treated with anti–vascular endothelial growth factor–targeted agents.

Clin Nucl Med. 42: e235-e241Rowe S.P. Gorin M.A. Hammers H.J. et al.

Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT.

Ann Nucl Med. 29: 877-882Yin Y. Campbell S.P. Markowski M.C. et al.

Inconsistent detection of sites of metastatic non-clear cell renal cell carcinoma with PSMA-targeted [18F] DCFPyL PET/CT.

Mol Imaging Biol. 21: 567-573Sawicki L.M. Buchbender C. Boos J. et al.

Diagnostic potential of PET/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience.

Eur J Nucl Med Mol Imaging. 44: 102-107Tang S. Meng M.V. Slater J.B. et al.

Metabolic imaging with hyperpolarized 13C pyruvate magnetic resonance imaging in patients with renal tumors—Initial experience.

Cancer. 127: 2693-2704Ursprung S. Woitek R. McLean M.A. et al.

Hyperpolarized 13C-Pyruvate Metabolism as a Surrogate for Tumor Grade and Poor Outcome in Renal Cell Carcinoma—A Proof of Principle Study.

Cancers. 14: 335Nakanishi Y. Kitajima K. Yamada Y. et al.

Diagnostic performance of 11C-choline PET/CT and FDG PET/CT for staging and restaging of renal cell cancer.

Ann Nucl Med. 32: 658-668Liu G. Jeraj R. Vanderhoek M. et al.

Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate.

Clin Cancer Res. 17: 7634-7644Horn K.P. Yap J.T. Agarwal N. et al.

FDG and FLT-PET for early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma.

Cancer Imaging. 15: 1-10Gerety E. Lawrence E. Wason J. et al.

Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design.

Ann Oncol. 26: 2113-2118Desar I.M. Stillebroer A.B. Oosterwijk E. et al.

111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.

J Nucl Med. 51: 1707-1715van Es S.C. Brouwers A.H. Mahesh S.V. et al.

89Zr-bevacizumab PET: potential early indicator of everolimus efficacy in patients with metastatic renal cell carcinoma.

J Nucl Med. 58: 905-910Withofs N. Signolle N. Somja J. et al.

18F-FPRGD2 PET/CT imaging of integrin αvβ3 in renal carcinomas: correlation with histopathology.

J Nucl Med. 56: 361-364Mena E. Owenius R. Turkbey B. et al.

[18F] Fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing αvβ3 and αvβ5 integrins.

Eur J Nucl Med Mol Imaging. 41: 1879-1888Soubra A. Hayward D. Dahm P. et al.

The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis.

World J Urol. 34: 1229-1237Crozier J. Papa N. Perera M. et al.

Comparative sensitivity and specificity of imaging modalities in staging bladder cancer prior to radical cystectomy: a systematic review and meta-analysis.

World J Urol. 37: 667-690Ha H.K. Koo P.J. Kim S.-J.

Diagnostic accuracy of F-18 FDG PET/CT for preoperative lymph node staging in newly diagnosed bladder cancer patients: a systematic review and meta-analysis.

Oncology. 95: 31-38Soubra A. Gencturk M. Froelich J. et al.

FDG-PET/CT for assessing the response to neoadjuvant chemotherapy in bladder cancer patients.

Clin Genitourinary Cancer. 16: 360-364Zattoni F. Incerti E. Colicchia M. et al.

Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study.

Abdom Radiol. 43: 2391-2399Kim S.-J. Koo P.J. Pak K. et al.

Diagnostic accuracy of C-11 choline and C-11 acetate for lymph node staging in patients with bladder cancer: a systematic review and meta-analysis.

World J Urol. 36: 331-340Schöder H. Ong S.C. Reuter V.E. et al.

Initial results with 11C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancer.

Mol Imaging Biol. 14: 245-251Treglia G. Sadeghi R. Annunziata S. et al.

Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the postchemotherapy management of patients with seminoma: systematic review and meta-analysis.

Biomed Res Int. 2014: 852681Asai S. Fukumoto T. Tanji N. et al.

Fluorodeoxyglucose positron emission tomography/computed tomography for diagnosis of upper urinary tract urothelial carcinoma.

Int J Clin Oncol. 20: 1042-1047Tanaka H. Yoshida S. Komai Y. et al.

Clinical value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in upper tract urothelial carcinoma: impact on detection of metastases and patient management.

Urologia Internationalis. 96: 65-72